GlassScriptPhysician profile
Shalanki Baiswar
NPI 1740431220
$872.42
in general payments reported to CMS, 2019-2025
15 companies · $310 in 2025
The $310 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2021: $146 · 2023: $18.48 · 2024: $180 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487 · Education: $21.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.22 |
| Education | $21.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $162.98 | 2021-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.93 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $118.04 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Ardelyx, INC. | $75.71 | 2023-2024 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $49.24 | 2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $48.60 | 2019-2025 | Rayaldee |
| Janssen Pharmaceuticals, INC | $28.50 | 2019 | |
| Baxter Healthcare | $26.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.00 | 2025 | |
| Ani Pharmaceuticals, INC. | $25.86 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $22.65 | 2024 | Veltassa |
| Fresenius USA Marketing, INC. | $21.44 | 2024 | Velphoro |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Travere Therapeutics, INC. | $3.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalanki Baiswar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.